Abstract

Rationale: Acute allograft rejection is one of the major complications after lung transplantation, and adequate and early recognition is important. Till now, the reference standard to detect acute rejection is the histopathological grading of transbronchial biopsies (TBBs). Acute rejection is characterised by high levels of activated T lymphocytes. Interleukin-2 (IL-2) binds specifically to high-affinity IL-2 receptors expressed on the cell membrane of activated T lymphocytes. The aim of this proof-of-concept study was to evaluate if non-invasive imaging with \(^{99m}\)Tc-HYNIC-IL-2 is able to detect acute rejection after lung transplantation.

Methods: \(^{99m}\)Tc-HYNIC-IL-2 scintigraphy (static, SPECT/CT of the lungs) was performed shortly before routine transbronchial biopsy (pathology as reference standard). Scans were scored as likely or unlikely for rejection, and semiquantitative analysis (target-to-background ratio) was performed.

Results: Thirteen patients were included of which 3 showed acute rejection at transbronchial biopsy; in 2 of these patients (scored as graded 2–3 at pathology), the scan was scored likely for rejection, and in 1 patient (scored grade 1 at pathology), the scan was scored unlikely. No correlation was found between biopsy results and semiquantitative analysis.

Conclusion: \(^{99m}\)Tc-HYNIC-IL-2 scintigraphy proved to be a good technique to detect grade 2 and 3 acute rejection in a small sample population of patients after lung transplantation. Larger studies are necessary to really show the added value of this non-invasive specific imaging technique over transbronchial biopsy. Alternatively, imaging with the PET tracer \(^{18}\)F-IL-2 may be useful for this purpose.

Keywords: \(^{99m}\)Tc-HYNIC-IL-2 scintigraphy, Lung transplantation, Rejection, SPECT/CT, Imaging
acute rejection, many centres perform surveillance TBB at fixed intervals during the first postoperative year, in addition to TBB in case of new symptoms or signs of rejection [4]. However, TBB has several limitations; it may cause bleeding and complications and may lead to sample errors. Therefore, a non-invasive imaging tool to detect rejection after transplantation is certainly needed.

Histopathological lesions, observed in acute rejection, show perivascular and interstitial mononuclear cell infiltrates in the pulmonary allograft [5], which are characterised by high levels of activated cytotoxic T lymphocytes overexpressing high-affinity interleukin-2 receptors (IL-2R), thus rendering T cells highly responsive to interleukin-2 (IL-2) [1]. IL-2 binds specifically to high-affinity IL-2R expressed on the cell membrane of activated T lymphocytes [6]. When labelled with a suitable radionuclide, IL-2 could be used as a probe to visualise lymphocyte infiltration by nuclear molecular imaging. To date, clinical research with radiolabelled IL-2 (e.g. 99mTc-HYNIC-IL-2 [7]) has been performed in various inflammatory diseases in over 1000 patients (inflammatory bowel disease, atherosclerosis, thyroiditis, diabetes type 1, etc.) [6, 8, 9].

In this proof-of-concept study, we investigated if acute allograft rejection can be detected by 99mTc-HYNIC-IL-2 scintigraphy, including single-photon emission computed tomography/computed tomography (SPECT/CT), in lung transplant recipients shortly after transplantation.

Methods and materials

Thirteen lung transplant recipients were included in this study. All recipients were > 18 years and provided written informed consent. Maintenance immunosuppression consisted of tacrolimus, mycophenolate mofetil, and prednisolone. Patients were clinically assessed prior to the scan to see if they had ongoing viral infections. The study was approved by the local Medical Ethics Committee (trial number 2009/219).

99mTc-HYNIC-IL-2 scintigraphy was performed shortly before the first routine bronchoscopy (TBB as reference standard) after transplantation (median 1 day, maximum 15 days). This bronchoscopy was performed several weeks after transplantation (median 36 days, minimum 19 days, maximum 126 days). 99mTc-HYNIC-IL-2 was produced as previously described [7], and the preferred injection dose was 185 MBq (range of administered dose 92–192 MBq). Planar anteroposterior images of the thorax and abdomen were acquired 60 min (range 55–67) after the administration of the radiopharmaceutical, followed by SPECT/CT of the thorax, SPECT for quantification, and low-dose CT for anatomic co-localization and attenuation correction. All images were acquired on a SPECT/CT gamma camera system (Siemens Symbia T, Siemens Medical Systems, Knoxville, TN, USA). The scans were analysed by two experienced nuclear medicine specialists (AG, RS) who were blinded to all patient information except sex, type of transplant (unilateral or bilateral), and time between transplantation and scan. The reviewers assessed the scans and scored the likelihood of acute rejection (rejection unlikely or rejection likely). If there was a disagreement between the reviewers, the case was reviewed together for consensus. The planar images were scored according to a grading system: grade 0, no uptake; grade 1, uptake lower than mediastinum; grade 2, uptake equal to mediastinum; and grade 3, uptake higher than mediastinum. Grades 2 and 3 were scores as rejection likely, and grades 0 and 1 as rejection unlikely. For the SPECT/CT images, the grading system was the same, but the grading scores were given for each lobe. If at least one lobe was scored with grade 2 or 3, this was regarded as rejection likely. Semiquantitative analysis on SPECT/CT images was performed by drawing the volume of interests around the lungs and dividing the number of counts per millilitre in the lung(s) by the counts per millilitre in reference tissues (aorta, bone marrow, and muscle) to calculate the target-to-background ratio (T/B). TBBs were assessed by an experienced pulmonary pathologist (WT). The TBBs were graded according to the criteria of the International Society for Heart and Lung Transplantation (ISHLT) [10]. On histology, acute rejection was defined as an ISHLT A score ≥ 1.

Correlation between IL-2 scintigraphy results and histology was assessed with Spearman’s rho. Additionally, sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV) with 95% confidence intervals (95% CI) were calculated.

Results

In Table 1 the characteristics of the 13 patients are presented. None of the patients showed signs of viral infection. Ten patients underwent bilateral lung transplantation and 3 unilateral transplantation. In 2 patients, no TBBs were available. In 1 patient, there was a non-accessible stenosis of the airway anastomosis during bronchoscopy. In the other patient, no assessable material was found in the biopsy. Three patients showed acute rejection in the TBB. In 2 of these patients, the scan was scored (both on planar as on SPECT images) as rejection likely. In the other patient, the scan was scored as rejection unlikely. In patients without rejection in the biopsies, no scans were scored as rejection likely. The correlation between the rejection on biopsies and the visual assessment of the scans was 0.77 (p = 0.006). The calculated sensitivity was 67% (95% CI 13–100%), the specificity was 100%, the positive predictive value was 100%, and the negative predictive value was 89% (68–100%). No
correlation was found between the rejection on biopsies and the T/B ratios on SPECT/CT (data not shown).

**Discussion**

In this proof-of-concept study, despite the low number of patients, we show that $^{99}$mTc-HYNIC-IL-2 scintigraphy is able to detect acute rejection in lung transplant recipients shortly after transplantation (Fig. 1). Maybe even more important, in future, it may provide a tool to avoid transbronchial biopsies when the imaging is negative or to improve the yield of these biopsies when positive. One of the benefits of imaging acute rejection with radiolabelled IL-2 is its non-invasive nature. TBBs, which are usually performed under general anaesthesia, are invasive and may lead to complications [1]. Furthermore, imaging with radiolabelled IL-2 can assess the entire lung, whereas TBBs are taken at random throughout the lung. This may lead to sampling errors.

---

**Table 1 Patient characteristics**

| Pt | Age (years) | Sex | Indication for transplant | Type of transplant | Pathology | ISHLT A | ISHLT B | ISHLT C | ISHLT D | Assessment of acute rejection | IL-2 imaging |
|----|-------------|-----|--------------------------|--------------------|-----------|---------|---------|---------|---------|-------------------------------|-------------|
| 1  | 46          | Female | Pulmonary hypertension | Bilateral           | 0         | 0       | 0       | 0       | Rejection unlikely            | Rejection unlikely |
| 2  | 47          | Female | COPD                     | Unilateral (L)     | 0         | 0       | 0       | 0       | Rejection unlikely            | Rejection unlikely |
| 3  | 30          | Male   | Cystic fibrosis          | Bilateral          | –         | 1R      | 0       | 0       | Rejection                      | Rejection unlikely |
| 4  | 51          | Male   | COPD                     | Bilateral          | 2         | 0       | 1       | 0       | Rejection unlikely            | Rejection likely   |
| 5  | 48          | Female | Pulmonary hypertension  | Bilateral          | 0         | 0       | 0       | 0       | Rejection unlikely            | Rejection unlikely |
| 6  | 52          | Female | COPD                     | Bilateral          | 0         | 1R      | 0       | 0       | Rejection unlikely            | Rejection unlikely |
| 7  | 63          | Male   | COPD                     | Bilateral          | 0         | 0       | 0       | 0       | Rejection unlikely            | Rejection unlikely |
| 8  | 62          | Male   | Fibrosis                 | Bilateral          | –         | –       | –       | –       | Rejection                      | Rejection unlikely |
| 9  | 53          | Male   | COPD                     | Bilateral          | 0         | 1R      | 0       | 0       | Rejection unlikely            | Rejection unlikely |
| 10 | 38          | Male   | Cystic fibrosis          | Bilateral          | 0         | 0       | 0       | 0       | Rejection unlikely            | Rejection unlikely |
| 11 | 59          | Female | COPD                     | Unilateral (R)     | 0         | 0       | 0       | 0       | Rejection unlikely            | Rejection unlikely |
| 12 | 47          | Male   | Alpha-1-antitrypsine deficiency | Bilateral | 3       | 1R      | 0       | 0       | Rejection                    | Rejection likely   |
| 13 | 64          | Female | Bronchiolitis            | Unilateral (R)     | 1         | 0       | 0       | 0       | Rejection                      | Rejection unlikely |

COPD chronic obstructive pulmonary disease, ISHLT The International Society for Heart and Lung Transplantation, IL-2 interleukin-2

---

**Fig. 1** $^{99}$mTc-HYNIC-IL-2 scintigraphy. Upper row images: anterior (left) and posterior (right) static view of a patient without rejection, showing intense uptake in the liver and moderate uptake in the mediastinum/blood pool. Lower row images: anterior (left) and posterior (right) static view of a patient with rejection, showing intense uptake in the liver, moderate uptake in mediastinum/blood pool, and increased uptake in the basal and posterior parts of the lungs (uptake equal to mediastinum).
The one patient with acute rejection in the TBB who had a negative scan showed only minimal rejection in the TBB (grade A1). On the other hand, the 2 patients with both a positive scan and acute rejection in the TBB showed mild to moderate acute rejection (grade 2 and 3). Therefore, the sensitivity of this SPECT technique may be too low to detect minimal rejection.

Since T cells with increased IL-2R expression are also upregulated in patients with viral infections [11], we advise to exclude patients with a possible viral infection before performing radiolabelled IL-2 imaging, to increase specificity. In our study, the patients were clinically assessed prior to the scan for viral infections and showed no signs of viral infection.

In this study, we used $^{99m}$Tc-HYNIC-IL-2, a SPECT radiopharmaceutical. Recently, we developed a new IL-2 tracer labelled with fluorine-18 ($^{18}$F), suitable for imaging with positron emission tomography/computed tomography (PET/CT) [12]. The use of PET/CT imaging improves image resolution and allows for the absolute quantification of IL-2 uptake in lung regions, most likely increasing sensitivity.

Our study suggests that non-invasive imaging with radiolabelled IL-2 can be a promising new tool in the detection and perhaps also the exclusion of acute rejection in patients after lung transplant. Further studies with larger patient populations are needed to determine the value of radiolabelled IL-2 imaging, preferably with the PET tracer. Possible applications of IL-2 imaging may be (1) in addition to TBB, to guide TBB to possible sites of rejection, or (2) to possibly avoid TBB in case of negative imaging.

Conclusion
In conclusion, in this proof-of-concept study, $^{99m}$Tc-HYNIC-IL-2 scintigraphy proved to be a good technique to detect grades 2 and 3 acute rejection in a small sample population of patients after lung transplantation. Larger studies are necessary to really show the added value of this non-invasive specific imaging technique over TBB. Alternatively, imaging with the PET tracer $^{18}$F-IL-2 may be useful for this purpose.

Availability of data and materials
The datasets used and/or analysed during the current study are available from the corresponding author on reasonable request.

Authors’ contributions
WvdB, EdV, EV, AS, and AG contributed to the design of the study. EdV and GL contributed to the production of the tracer. WvdB, EV, and AG contributed to the inclusion of the patients. ET, RS, AS, and AG interpreted the data. ET, RS, AS, and AG wrote the manuscript. ET, WvdB, EdV, EV, WT, GL, RS, AS, and AG contributed to the drafting and revision of the manuscript. All authors read and approved the final manuscript.

Ethics approval and consent to participate
All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. The local institutional review board approved this retrospective study and waived the requirement for informed consent.

Consent for publication
All authors provide their consent for publication.

Competing interests
The authors declare that they have no competing interests.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Author details
1Medical Imaging Center, Department of Nuclear Medicine and Molecular Imaging, University of Groningen, University Medical Center Groningen, Hanzeplein 1, 9700 RB Groningen, The Netherlands. 2Department of Respiratory Diseases, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands. 3Department of Pathology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands. 4Department of Biomedical Photonic Imaging, University of Twente, Enschede, The Netherlands. 5Nuclear Medicine Unit, Department of Medical-Surgical Sciences and Translational Medicine, Sapienza University of Rome, Rome, Italy.

Received: 25 February 2019 Accepted: 23 April 2019
Published online: 10 May 2019

References
1. Knoop C, Haverich A, Fischer S. Immunosuppressive therapy after human lung transplantation. Eur Respir J. 2004;23:159–71.
2. Gotvay MB, Dawn SK, Sellami D, Golden JA, Reddy GP, Keith FM, Webb WR. Acute rejection following lung transplantation: limitations in accuracy of thin-section CT for diagnosis. Radiology. 2001;221:207–12.
3. Speck NE, Schuurmans MM, Benden C, Robinson CA, Huber LC. Plasma and bronchoalveolar lavage samples in acute lung allograft rejection: the potential role of cytokines as diagnostic markers. Respir Res. 2017;18:151–017-0634-6.
4. Kukafka DS, O’Brien GM, Furukawa S, Criner GJ. Surveillance bronchoscopy in lung transplant recipients. Chest. 1997;111:377–81.
5. Palmer SM, Burch LH, Davis RD, Herczyk WF, Howell DN, Reinsmoen NL, Schwartz DA. The role of innate immunity in acute allograft rejection after lung transplantation. Am J Respir Crit Care Med. 2003;168:629–32.
6. Signore A, Picarelli A, Annozavi A, Britton KE, Grossman AB, Bonanno E, et al. 123I-Interleukin-2: biochemical characterization and in vivo use for imaging autoimmune diseases. Nucl Med Commun. 2003;24:306–16.
7. D’Alessandria C, di Gialleonardo V, Chianelli M, Mather SJ, de Vries EF, Scopinaro F, Dierck RA, et al. Synthesis and optimization of the labeling procedure of $^{99m}$Tc-HYNIC-interleukin-2 for in vivo imaging of activated T lymphocytes. Mol Imaging Biol. 2010;12:539–46.
8. Annozavi A, Biancone L, Cavigilia R, Chianelli M, Capriotti G, Matther SJ, et al. $^{99m}$Tc-interleukin-2 and ($^{99m}$Tc-HMPAO) granulocyte scintigraphy in patients with inactive Crohn’s disease. Eur J Nucl Med Mol Imaging. 2003;30:374–82.
9. Glaudemans AWJM, Bonnanno E, Galli F, Zeebregts CJ, de Vries EEJ, Koole M, et al. In vivo and in vitro evidence that 99mTc-HYNIC-interleukin-2 is able to detect T lymphocytes in vulnerable atherosclerotic plaques of the carotid artery. Eur J Nucl Med Mol Imaging. 2014;41:1710–9.

10. Stewart S, Fishbein MC, Snell GI, Berry GJ, Boehler A, Burke MM, et al. Revision of the 1996 working formulation for the standardization of nomenclature in the diagnosis of lung rejection. J Heart Lung Transplant. 2007;26:1229–42.

11. Bachmann MF, Wolint P, Walton S, Schwarz K, Oxenius A. Differential role of IL-2R signaling for CD8+ T cell responses in acute and chronic viral infections. Eur J Immunol. 2007;37:1502–12.

12. Di Giacomo V, Signore A, Willemsen AT, Sijbesma JW, Dierckx RA, de Vries EF. Pharmacokinetic modeling of N-(4-[(18)F]fluorobenzoyl)interleukin-2 binding to activated lymphocytes in an xenograft model of inflammation. Eur J Nucl Med Mol Imaging. 2012;39:1551–60.